Cargando…

Predictive Value of MUC5AC Signature in Pancreatic Ductal Adenocarcinoma: A Hypothesis Based on Preclinical Evidence

Mucin 5AC (MUC5AC) glycoprotein plays a crucial role in carcinogenesis and drug sensitivity in pancreatic ductal adenocarcinoma (PDAC), both individually and in combination with other mucins. Its function and localization are glycoform-specific. The immature isoform (detected by the CLH2 monoclonal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Manne, Ashish, Kasi, Anup, Esnakula, Ashwini Kumar, Paluri, Ravi Kumar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10178741/ https://www.ncbi.nlm.nih.gov/pubmed/37175794 http://dx.doi.org/10.3390/ijms24098087

Ejemplares similares

Understanding the Clinical Impact of MUC5AC Expression on Pancreatic Ductal Adenocarcinoma
por: Manne, Ashish, et al.
Publicado: (2021)

Differential Expression and Diagnostic Value of MUC5AC Glycoforms in Pancreatic Ductal Adenocarcinoma
por: Manne, Ashish, et al.
Publicado: (2023)

Understanding the Clinical Significance of MUC5AC in Biliary Tract Cancers
por: Benson, Katherine K., et al.
Publicado: (2023)

Survival Outcomes of Pancreatic Intraepithelial Neoplasm (PanIN) versus Intraductal Papillary Mucinous Neoplasm (IPMN) Associated Pancreatic Adenocarcinoma
por: McGinnis, Timothy, et al.
Publicado: (2020)

Aberrant methylation of MUC1 and MUC4 promoters are potential prognostic biomarkers for pancreatic ductal adenocarcinomas
por: Yokoyama, Seiya, et al.
Publicado: (2016)

Impact of the COVID-19 Pandemic on Management of Patients with Metastatic Pancreatic Ductal Adenocarcinoma in the United States
por: Paluri, Ravi, et al.
Publicado: (2022)

MUC1-C dictates neuroendocrine lineage specification in pancreatic ductal adenocarcinomas
por: Luan, Zhou, et al.
Publicado: (2021)

Associations between the Expression of Mucins (MUC1, MUC2, MUC5AC, and MUC6) and Clinicopathologic Parameters of Human Breast Ductal Carcinomas
por: Do, Sung-Im, et al.
Publicado: (2013)

Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models
por: Hoare, Owen, et al.
Publicado: (2021)

Is Cell-Free DNA Testing in Pancreatic Ductal Adenocarcinoma Ready for Prime Time?
por: Sheel, Ankur, et al.
Publicado: (2022)

Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin
por: Gold, David V, et al.
Publicado: (2013)

Advances in pancreatic cancer biomarkers
por: Hasan, Syed, et al.
Publicado: (2019)

Pancreatic Ductal Adenocarcinoma: Preclinical in vitro and ex vivo Models
por: Gündel, Beate, et al.
Publicado: (2021)

Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies
por: Pham, Thao N. D., et al.
Publicado: (2021)

Bile accelerates carcinogenic processes in pancreatic ductal adenocarcinoma cells through the overexpression of MUC4
por: Gál, Eleonóra, et al.
Publicado: (2020)

Overexpression of MUC1 Induces Non-Canonical TGF-β Signaling in Pancreatic Ductal Adenocarcinoma
por: Bose, Mukulika, et al.
Publicado: (2022)

Therapeutic options for ampullary carcinomas. A review
por: Regalla, Dileep Kumar Reddy, et al.
Publicado: (2019)

The limits of molecular signatures for pancreatic ductal adenocarcinoma subtyping
por: Lautizi, Manuela, et al.
Publicado: (2022)

MUC13 Interaction with Receptor Tyrosine Kinase HER2 Drives Pancreatic Ductal Adenocarcinoma Progression
por: Khan, Sheema, et al.
Publicado: (2016)

MUC16 contributes to the metastasis of pancreatic ductal adenocarcinoma through focal adhesion mediated signaling mechanism
por: Muniyan, Sakthivel, et al.
Publicado: (2016)

Mimics of pancreatic ductal adenocarcinoma
por: Al-Hawary, Mahmoud M., et al.
Publicado: (2013)

Evaluation of MUC1, MUC2, MUC5AC, and MUC6 Expression Differences in Lung Adenocarcinoma Subtypes by Using a Final Immunoreactivity Score (FIRS)
por: Buyuk, Melek, et al.
Publicado: (2023)

Review of the endocrine organ–like tumor hypothesis of cancer cachexia in pancreatic ductal adenocarcinoma
por: Yu, Ying-Chun, et al.
Publicado: (2022)

Ion Channel Signature in Healthy Pancreas and Pancreatic Ductal Adenocarcinoma
por: Schnipper, Julie, et al.
Publicado: (2020)

Preclinical models of pancreatic ductal adenocarcinoma: challenges and opportunities in the era of precision medicine
por: Yu, Yiqi, et al.
Publicado: (2021)

Preliminary Development and Testing of C595 Radioimmunoconjugates for Targeting MUC1 Cancer Epitopes in Pancreatic Ductal Adenocarcinoma
por: Hull, Ashleigh, et al.
Publicado: (2022)

Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis
por: Mayerle, Julia, et al.
Publicado: (2018)

MUC1, MUC2, MUC5AC, and MUC6 in colorectal cancer: expression profiles and clinical significance
por: Betge, Johannes, et al.
Publicado: (2016)

Silencing of MUC20 suppresses the malignant character of pancreatic ductal adenocarcinoma cells through inhibition of the HGF/MET pathway
por: Chen, Syue-Ting, et al.
Publicado: (2018)

A Novel Association of Neuropilin-1 and MUC1 in Pancreatic Ductal Adenocarcinoma: Role in Induction of VEGF Signaling and Angiogenesis
por: Zhou, Ru, et al.
Publicado: (2016)

The Expression Profile and Textural Characteristics of C595-Reactive MUC1 in Pancreatic Ductal Adenocarcinoma for Targeted Radionuclide Therapy
por: Hull, Ashleigh, et al.
Publicado: (2020)

Preclinical mouse models for immunotherapeutic and non-immunotherapeutic drug development for pancreatic ductal adenocarcinoma
por: He, Mengni, et al.
Publicado: (2020)

DNA Damage Repair Deficiency in Pancreatic Ductal Adenocarcinoma: Preclinical Models and Clinical Perspectives
por: Stoof, Jojanneke, et al.
Publicado: (2021)

Prognostic Fifteen-Gene Signature for Early Stage Pancreatic Ductal Adenocarcinoma
por: Chen, Dung-Tsa, et al.
Publicado: (2015)

Circular RNA Signature Predicts Gemcitabine Resistance of Pancreatic Ductal Adenocarcinoma
por: Shao, Feng, et al.
Publicado: (2018)

Establishing and validating an ADCP-related prognostic signature in pancreatic ductal adenocarcinoma
por: Zhang, Deyu, et al.
Publicado: (2022)

Novel prognostic gene signature for pancreatic ductal adenocarcinoma based on hypoxia
por: Ren, Min, et al.
Publicado: (2023)

Desmoplastic stromal signatures predict patient outcomes in pancreatic ductal adenocarcinoma
por: Mascharak, Shamik, et al.
Publicado: (2023)

Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial
por: Huffman, Brandon M., et al.
Publicado: (2023)

Correction: Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_30uh7s0oo097dmj2bg63jc360r